Our drug delivery platform allows the delivery of medicines through the pulmonary route. Patients benefit from the convenient, needle-free and discreet approach.
The platform includes inhalation powders made with our Technosphere® particles together with our novel inhaler devices. A wide variety of active pharmaceutical ingredients (API) can be loaded onto our particles, which are then filled into our innovative, proprietary inhaler devices.
A rapid onset of therapeutic action, avoidance of first pass elimination, and high bio-availability characterize our unique, needle-free approach to drug delivery. Our dry powder inhaler (DPI) systems are available in two types, including the multi-use DreamBoat™ and the single-use, disposable Cricket™ inhalers.
MannKind's unique delivery science enables effective inhalation of dry powder formulations tailored to therapeutic need.
MannKind's Technosphere particles are made from the novel, inert excipient fumaryl diketopiperazine (FDKP). Technosphere particles can accommodate a wide variety of APIs and still give powders within a consistent and narrow particle size range. The resulting powders, such as Technosphere insulin, dissolve extremely fast after inhalation and deliver the API directly into the arterial circulation with excellent systemic exposure.
Additionally, the processes for Technosphere inhalation powder formation can be readily adjusted to target desired particle sizes that may be required by specific therapies.
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.
In addition, MannKind is applying our novel technologies and services to support partner development efforts.